[{"address1": "7171 Frederick-Banting, Building 2", "address2": "Suite 270 St-Laurent", "city": "Montreal", "state": "QC", "zip": "H4S 1Z9", "country": "Canada", "phone": "857 412 7018", "website": "https://www.reparerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.", "fullTimeEmployees": 129, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steve  Forte CPA", "age": 46, "title": "President, CFO, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 631996, "exercisedValue": 0, "unexercisedValue": 1765836}, {"maxAge": 1, "name": "Dr. Daniel  Durocher Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank  Sicheri Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Agnel  Sfeir Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Alves", "age": 46, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Belanger", "title": "Executive Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph P. O'Connell M.D.", "age": 71, "title": "Executive Vice President of Clinical Development and Medical Affairs", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.65, "open": 2.64, "dayLow": 2.62, "dayHigh": 2.65, "regularMarketPreviousClose": 2.65, "regularMarketOpen": 2.64, "regularMarketDayLow": 2.62, "regularMarketDayHigh": 2.65, "payoutRatio": 0.0, "beta": 0.962, "forwardPE": -0.8922559, "volume": 1167676, "regularMarketVolume": 1167676, "averageVolume": 1158864, "averageVolume10days": 951390, "averageDailyVolume10Day": 951390, "bid": 1.89, "ask": 3.39, "bidSize": 2, "askSize": 2, "marketCap": 114237160, "fiftyTwoWeekLow": 0.89, "fiftyTwoWeekHigh": 2.66, "allTimeHigh": 46.44, "allTimeLow": 0.89, "priceToSalesTrailing12Months": 9.624023, "fiftyDayAverage": 2.3475, "twoHundredDayAverage": 1.754225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1650250, "profitMargins": 0.0, "floatShares": 22862404, "sharesOutstanding": 43108362, "sharesShort": 437896, "sharesShortPriorMonth": 352361, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.010199999, "heldPercentInsiders": 0.00254, "heldPercentInstitutions": 0.6415, "shortRatio": 0.31, "shortPercentOfFloat": 0.0162, "impliedSharesOutstanding": 43108362, "bookValue": 2.678, "priceToBook": 0.9895445, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -72200000, "trailingEps": -1.7, "forwardEps": -2.97, "enterpriseToRevenue": 0.139, "enterpriseToEbitda": -0.022, "52WeekChange": 1.1721311, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 2.65, "targetHighPrice": 3.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 112604000, "totalCashPerShare": 2.62, "ebitda": -76462000, "totalDebt": 342000, "quickRatio": 10.404, "currentRatio": 10.708, "totalRevenue": 11870000, "debtToEquity": 0.297, "revenuePerShare": 0.278, "returnOnAssets": -0.29721, "returnOnEquity": -0.49778, "grossProfits": 47883000, "freeCashflow": -42824248, "operatingCashflow": -70148000, "grossMargins": 4.03395, "ebitdaMargins": 0.0, "operatingMargins": -0.03701, "financialCurrency": "USD", "symbol": "RPTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Repare Therapeutics Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1592573400000, "regularMarketChangePercent": 0.0, "regularMarketPrice": 2.65, "exchange": "NMS", "messageBoardId": "finmb_435208167", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Repare Therapeutics Inc.", "epsTrailingTwelveMonths": -1.7, "epsForward": -2.97, "fiftyDayAverageChange": 0.3025, "fiftyDayAverageChangePercent": 0.12886049, "twoHundredDayAverageChange": 0.8957751, "twoHundredDayAverageChangePercent": 0.51063865, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-06-19", "cryptoTradeable": false, "corporateActions": [{"header": "Delisting", "message": "RPTX was delisted effective Jan. 29, 2026", "meta": {"eventType": "DELISTING", "dateEpochMs": 1769662800000}}], "regularMarketTime": 1769547601, "marketState": "CLOSED", "regularMarketChange": 0.0, "regularMarketDayRange": "2.62 - 2.65", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1158864, "fiftyTwoWeekLowChange": 1.7600001, "fiftyTwoWeekLowChangePercent": 1.9775282, "fiftyTwoWeekRange": "0.89 - 2.66", "fiftyTwoWeekHighChange": -0.00999999, "fiftyTwoWeekHighChangePercent": -0.0037593949, "fiftyTwoWeekChangePercent": 117.213104, "earningsTimestampStart": 1763154000, "earningsTimestampEnd": 1763154000, "isEarningsDateEstimate": true, "displayName": "Repare Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]